Niagen Bioscience (NAGE) Income from Continuing Operations (2010 - 2026)
Niagen Bioscience (NAGE) reported Income from Continuing Operations of 6318000.0 for Q1 2026, up 24.79% year-over-year from 5063000.0 in Q1 2025, and up 52.9% quarter-over-quarter from 4132000.0 in Q4 2025.
Niagen Bioscience (NAGE) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 17 years of Income from Continuing Operations data on file, last reported at 6318000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 6318000.0, up 24.79% year-over-year; the trailing twelve-month figure through Mar 2026 was 18637000.0 (up 32.13% YoY), and the FY2025 annual result was 17382000.0, up 103.3% from the prior year.
- Income from Continuing Operations advanced to 6318000.0 in Q1 2026 per NAGE's latest filing, from 4132000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 7179000.0 in Q4 2024 and troughed at 7740000.0 in Q1 2022.
- A 5-year average of 505588.24 and a median of 15000.0 in 2024 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 24160.0% in 2025 and fell as far as 42.44% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 1444000.0 in 2022, then surged by 107.89% to 114000.0 in 2023, then surged by 6197.37% to 7179000.0 in 2024, then plunged by 42.44% to 4132000.0 in 2025, then soared by 52.9% to 6318000.0 in 2026.
- Business Quant data shows NAGE's Income from Continuing Operations at 6318000.0 in Q1 2026, 4132000.0 in Q4 2025, and 4578000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Niagen Bioscience | 280.11 Mn | 213.56 Mn | 19.98 Mn | 6.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.32 Mn |
| Dec 31, 2025 | 4.13 Mn |
| Sep 30, 2025 | 4.58 Mn |
| Jun 30, 2025 | 3.61 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Dec 31, 2024 | 7.18 Mn |
| Sep 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | -492,000.00 |
| Dec 31, 2023 | 114,000.00 |
| Sep 30, 2023 | -959,000.00 |
| Jun 30, 2023 | -2.19 Mn |
| Mar 31, 2023 | -1.97 Mn |
| Dec 31, 2022 | -1.44 Mn |
| Sep 30, 2022 | -3.07 Mn |
| Jun 30, 2022 | -6.40 Mn |
| Mar 31, 2022 | -7.74 Mn |
| Dec 31, 2021 | -5.33 Mn |
| Sep 30, 2021 | -8.86 Mn |
| Jun 30, 2021 | -5.57 Mn |